Targets › VIM
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.
Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. (UniProt, P08670)
Open in Phaseline: the race on VIM, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Filamon | KESONOTIDE™ hGIIA-Vimentin inhibitor | VIM | Phase 1 | Prostate Cancers | Oct 2027 |
Prostate Cancers (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.